Table 1 Patient characteristics and outcomes for subgroups of MPN and for hospitalised patients.

From: Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm

   ET PV MF Other pa Total Outpatient Inpatient ISARICb pc
Number n 28(36%) 18(23%) 27(35%) 4(5%)   77 14(18%) 63(82%) 60,430  
Age Median (IQR) 78(71–84) 73(54–76) 73(61–81) 81(57–88) 0.06 74(64–82) 63.5(51–79) 75(67–82) 73  
Gender Female 12(43%) 7(39%) 13(48%) 0 0.38 32(42%) 7(50%) 25(40%) 25,899(43%) 0.6
Male 16(57%) 11(61%) 14(52%) 4(100%)   45(58%) 7(50%) 38(60%) 34,422(57%)  
Ethnicity Asian 2(7%) 2(11%) 1(4%) 0 0.96 5(7%) 1(7%) 4(6%)   
Black 1(4%) 1(6%) 1(4%) 0   3(4%) 1(7%) 2(3%)   
White 24(89%) 15(83%) 25(93%) 4(100%)   68(89%) 12(86%) 56(90%)   
Active treatment Observation only 2(7%) 1(6%) 3(11%) 1(25%) 0.53 7(9%) 2(14%) 5(8%)   
Active treatment 26(93%) 17(94%) 24(89%) 3(75%)   70(91%) 12(86%) 58(92%)   
  Ruxolitinib 2(7%) 4(22%) 19(70%) 1(25%) <0.01 26(34%) 3(21%) 23(37%)   
Number of additional co-morbidities None 9(32%) 8(44%) 12(44%) 1(25%) 0.14 30(39%) 9(64%) 18(29%)   
1 or 2 9(32%) 9(50%) 13(48%) 3(75%)   34(44%) 4(29%) 30(48%)   
3 or 4 10(36%) 1(6%) 2(7%) 0   13(17%) 1(7%) 15(24%)   
Co-morbidity Hypertension 14(50%) 4(22%) 12(44%) 1(25%) 0.25 31(40%) 3(21%) 28(44%) 16,074(32%) 0.03
Diabetes 8(29%) 3(17%) 5(19%) 0 0.63 16(21%) 1(7%) 15(24%) 9617(14%) 0.02
Hospital admission Outpatient 1(4%) 6(33%) 6(22%) 1(25%) 0.04 14(18%)     
Inpatient 27(96%) 12(67%) 21(78%) 3(75%)   63(82%)     
ICU admission Not known 0 0 1(4%) 1(25%) 0.79 1(1%)   2(3%)   
Not indicated 23(82%) 15(83%) 23(85%) 3(75%)   63(82%)   50(79%)   
Admitted to ICU 5(18%) 3(17%) 3(11%) 0   11(14%)   11(18%) 9754(16%) 0.73
Maximal respiratory support None 3(11%) 9(50%) 9(33%) 2(25%) 0.14 23(30%) 14(100%) 9(14%)   
Oxygen 15(54%) 6(33%) 11(41%) 2(50%)   34(44%) 0 34(54%)   
High Flow 5(18%) 0 2(7.4%) 0   7(9%) 0 7(11%)   
CPAP/NIV 1(4%) 0 3(11%) 0   4(5%) 0 4(6%)   
Intubation 4(14%) 3(17%) 2(7%) 0   9(12%) 0 9(14%) 5643(10%) 0.29
Mortality Died 13(46%) 8(44%) 12(44%) 2(50%) 1 35(45%) 2(14%) 33(52%) 17,031(28%) <0.01
Ongoing 1(4%) 0 1(4%) 0   2(3%) 1(7%) 1(2%) 3209(5%) 0.26
Recovered 14(50%) 10(56%) 14(52%) 2(50%)   40(52%) 11(79%) 29(46%) 26,191(57%) 0.09
Other outcomes Venous thrombosis 1(PE; 4%) 0 1(PE; 4%) 0 0.98 2(3%) 0 2(3%)   
  Arterial thrombosis 1(CVA; 4%) 1(MI; 6%) 0 0 0.66 2(3%) 0 2(3%)   
  Bleed 2(MB + NMB; 7%) 0 1(NMB; 4%) 0 1 3(4%) 0 3(5%)   
  1. p values < 0.05 are highlighted in bold.
  2. CVA cerebrovascular accident, ET essential thrombocythemia, IQR interquartile range, MB major bleed (>2 units RBC or intracerebral), MI myocardial infarction, MF myelofibrosis (primary and secondary), NMB non-major bleed (required medical intervention/<3 units RBC transfusion), PE pulmonary embolism, PV polycythemia rubra vera.
  3. aFisher’s exact test (two-sided) or Kruskall–Wallis test comparing MPN subgroups.
  4. bMost recent results of ISARIC study [6].
  5. cΧ2 test (two-sided) comparing inpatient and ISARIC cohorts.